The current week's news sentiment is NEGATIVE for Sun Pharma's stock. Both news headlines report the USFDA issuing a warning letter to Sun Pharma's Dadra unit due to manufacturing practice violations, which has caused the stock to slip or extend its fall.

Notable events:

* USFDA warning letter to Sun Pharma's Dadra unit
* Manufacturing practice violations at the Dadra unit

The news tone is NEGATIVE, indicating a potential negative impact on the stock price. The historical similar news and price impact suggest that the stock has previously reacted negatively to such news, with price impacts ranging from -1.00% to -4.41%.